Ablynx proposes to strengten its board
Ablynx announced that Dr Roger Perlmutter and Dr Russell G. Greig will be proposed as Independent Non-Executive Directors at the Company's forthcoming Extraordinary General Meeting of its shareholders at the beginning of November 2012.
Dr Perlmutter was Executive Vice President, Research and Development, at Amgen Inc from 2001 to 2012. Before joining Amgen, he was the Executive Vice President of Worldwide Basic Research and Preclinical Development at Merck and Co. Prior to joining Merck, Dr Perlmutter had been Professor and founding Chairman of the Department of Immunology at the University of Washington, Seattle, USA.
Dr Perlmutter is currently a Director of StemCells Inc. and the Immune Design Corporation. He is also Chairman of the Board of Trustees of Reed College and a Director of the Institute for Systems Biology. He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science and a past President of the American Association of Immunologists. Ablynx is the first potential Board mandate that Dr Perlmutter has accepted outside the USA.
Dr Greig has more than 30 years' experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial operations. He spent the majority of his career at GlaxoSmithKline, where he held a number of positions including GSK's President of Pharmaceuticals International from 2003 to 2008 and Senior Vice President Worldwide Business Development. From 2008 to 2010, Dr Greig was also President of SR One, GSK's Corporate Venture Group. He is currently Chairman of Syntaxin (UK), AM Pharma (The Netherlands) and Isconova (Sweden) as well as a Director of Tigenix (Belgium). He also acts as a consultant to Genocea (US), BigDNA (Scotland), Edinburgh BioQuarter (Scotland), and Kurma Life Sciences (France). He served as acting CEO at Genocea and Isconova for an interim period. He is also a member of the Scottish Scientific Advisory Committee.
Other news from the department people
